Topline 24-month data showed a clinically meaningful reduction in geographic atrophy lesion growth from baseline for intravitreal pegcetacoplan compared with sham in the phase 3 DERBY and OAKS studies, according to Apellis Pharmaceuticals.
In the DERBY study, geographic atrophy (GA) lesion growth was reduced by 19% with monthly pegcetacoplan (P = .0004) and 16% with every-other-month pegcetacoplan (P = .0030). In the OAKS study, GA lesion growth was reduced by 22% with monthly treatment (P < .0001) and 18% with every other-month-treatment (P = .0002).
Additionally, pegcetacoplan compared